Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

Martin J. Edelman

doi:10.1586/14737140.1.2.229

Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

Martin J. Edelman

University of Maryland

Research output: Contribution to journal › Review article › peer-review

Abstract

Of the patients that undergo complete resection of early-stage non-small cell lung cancer (NSCLC), 30-60% will die. Postoperative adjuvant chemotherapy has yet to demonstrate an unequivocal benefit and there are significant difficulties in administering postoperative chemotherapy to patients with the significant comorbidities found in NSCLC. Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments.

Original language	English
Pages (from-to)	229-235
Number of pages	7
Journal	Expert Review of Anticancer Therapy
Volume	1
Issue number	2
DOIs	https://doi.org/10.1586/14737140.1.2.229
State	Published - 2001

Keywords

Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Biomarkers, Tumor/metabolism
Carcinoma, Non-Small-Cell Lung/classification
Chemotherapy, Adjuvant/methods
Clinical Trials as Topic
Humans
Lung Neoplasms/classification
Neoadjuvant Therapy/methods
Neoplasm Staging
Recurrence

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.1.2.229

Cite this

@article{255f7fcc65d945f19d152bf1ad777c9a,

title = "Neoadjuvant chemotherapy in early-stage non-small cell lung cancer",

abstract = "Of the patients that undergo complete resection of early-stage non-small cell lung cancer (NSCLC), 30-60% will die. Postoperative adjuvant chemotherapy has yet to demonstrate an unequivocal benefit and there are significant difficulties in administering postoperative chemotherapy to patients with the significant comorbidities found in NSCLC. Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments.",

keywords = "Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Biomarkers, Tumor/metabolism, Carcinoma, Non-Small-Cell Lung/classification, Chemotherapy, Adjuvant/methods, Clinical Trials as Topic, Humans, Lung Neoplasms/classification, Neoadjuvant Therapy/methods, Neoplasm Staging, Recurrence",

author = "Edelman, {Martin J.}",

year = "2001",

doi = "10.1586/14737140.1.2.229",

language = "English",

volume = "1",

pages = "229--235",

journal = "Expert Review of Anticancer Therapy",

issn = "1473-7140",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

AU - Edelman, Martin J.

PY - 2001

Y1 - 2001

N2 - Of the patients that undergo complete resection of early-stage non-small cell lung cancer (NSCLC), 30-60% will die. Postoperative adjuvant chemotherapy has yet to demonstrate an unequivocal benefit and there are significant difficulties in administering postoperative chemotherapy to patients with the significant comorbidities found in NSCLC. Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments.

AB - Of the patients that undergo complete resection of early-stage non-small cell lung cancer (NSCLC), 30-60% will die. Postoperative adjuvant chemotherapy has yet to demonstrate an unequivocal benefit and there are significant difficulties in administering postoperative chemotherapy to patients with the significant comorbidities found in NSCLC. Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments.

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Biomarkers, Tumor/metabolism

KW - Carcinoma, Non-Small-Cell Lung/classification

KW - Chemotherapy, Adjuvant/methods

KW - Clinical Trials as Topic

KW - Humans

KW - Lung Neoplasms/classification

KW - Neoadjuvant Therapy/methods

KW - Neoplasm Staging

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=0035558041&partnerID=8YFLogxK

U2 - 10.1586/14737140.1.2.229

DO - 10.1586/14737140.1.2.229

M3 - Review article

C2 - 12113028

SN - 1473-7140

VL - 1

SP - 229

EP - 235

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

IS - 2

ER -

Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this